Education > XRAY > Metastatic Breast Cancer

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 79

Relevance: High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Expanded access to Medicaid coverage under the Affordable Care Act is linked to reduced cancer mortality

Most relevant for: People with breast, colorectal or lung cancer.

In 2014 the Affordable Care Act expanded Medicaid coverage. How did this affect healthcare for cancer patients? This study shows that deaths from breast, colorectal and lung cancer are lower in states that chose to expand Medicaid compared to states that did not. Early diagnosis was linked to lower death rates. This suggests that increased healthcare access may lead to earlier cancer detection and better outcomes, including lower mortality. (3/31/2021)

Read More
Expanded access to Medicaid coverage under the Affordable Care Act is linked to reduced cancer mortality

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Guideline : COVID vaccines for people with cancer

Most relevant for: Cancer patients, their family and caregivers

Should cancer patients get a COVID vaccine? The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) provide guidance for people with cancer. These experts recommend that most cancer patients get vaccinated as soon as the vaccine is offered (unless they are allergic to a vaccine component). Cancer patients who have had recent surgery may delay vaccination a few days after surgery. Those with a suppressed immune system are advised to delay getting the vaccine until they’re healthy enough to do so. (2/1/21)

Read More
COVID vaccines for people with cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : How breast cancer patients experience hormone therapy

Most relevant for: Breast cancer patients taking or considering taking hormone therapy

Side effects from hormone therapy are a common reason that many men and women with hormone receptor-positive breast cancer stop treatment early. Some people never start hormone therapy. This study asked patients about their experiences with hormone (or endocrine) therapy. The results suggest that there may be ways to improve the number of patients who stick with therapy. Patients need better ways to manage hormone therapy-related side effects. (1/19/21)

Read More
How breast cancer patients experience hormone therapy

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer

Most relevant for: People with metastatic triple-negative breast cancer

The ASCENT study confirmed an earlier study and showed that the smart drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)

Read More
Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer

Relevance: Medium-Low

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Animal Studies

pointerResearch Timeline

Study : The buzz about honeybee venom: Promising early research to treat breast cancer

Most relevant for: People with breast cancer particularly those with HER2-positive or triple-negative breast cancer.

Early research showed that melittin, an ingredient in honeybee venom, may be used to treat HER2-positive and triple-negative breast cancers. This study found that melittin can kill cancer cells. The chemotherapy drug docetaxel more effectively killed breast cancer cells in mice when combined with melittin. It is not known whether melittin would be safe or affect cancer growth in people. While promising, more research must be done before melittin could be used to treat people.  (11/10/20)

Read More
The buzz about honeybee venom: Promising early research to treat breast cancer

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More
Coping with chemotherapy-induced hair loss

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Guideline : FDA issues alert on a drug combination to treat triple-negative breast cancer

Most relevant for: People with metastatic triple-negative breast cancer

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

Read More
FDA issues alert on a drug combination to treat triple-negative breast cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Study : Among women with breast cancer, who should have genetic testing for an inherited mutation?

Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer

Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)

Read More
Among women with breast cancer, who should have genetic testing for an inherited mutation?

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Most relevant for: People with metastatic breast cancer with an inherited mutation or tumor with a BRCA mutation

Early results of a small study showed that women with metastatic breast cancer and an inherited  mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)

Read More
Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer

Most relevant for: Patients with Her2-positive metastatic breast cancer

The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This  approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)

Read More
FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer

This Portal Sponsored By:

Centers for Disease Control